Intelligent Bio Solutions (NASDAQ:INBS) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Intelligent Bio Solutions (NASDAQ:INBS) to a sell rating in a research note issued to investors on Saturday morning.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Intelligent Bio Solutions in a research report on Thursday, January 22nd. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has an average rating of “Sell”.

Intelligent Bio Solutions Price Performance

INBS stock opened at $7.86 on Friday. Intelligent Bio Solutions has a 12 month low of $4.03 and a 12 month high of $27.50. The firm’s 50-day moving average is $8.80 and its 200 day moving average is $11.48. The company has a market capitalization of $9.59 million, a PE ratio of -0.46 and a beta of 4.48.

Intelligent Bio Solutions (NASDAQ:INBS) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($3.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.50) by ($2.00). Intelligent Bio Solutions had a negative net margin of 330.00% and a negative return on equity of 276.73%. The company had revenue of $1.11 million during the quarter, compared to analysts’ expectations of $4.80 million. Sell-side analysts forecast that Intelligent Bio Solutions will post -1.25 EPS for the current fiscal year.

Institutional Investors Weigh In On Intelligent Bio Solutions

A number of hedge funds and other institutional investors have recently bought and sold shares of INBS. ADAR1 Capital Management LLC purchased a new stake in shares of Intelligent Bio Solutions during the 3rd quarter valued at $435,000. Alyeska Investment Group L.P. boosted its holdings in Intelligent Bio Solutions by 9.7% in the third quarter. Alyeska Investment Group L.P. now owns 673,492 shares of the company’s stock worth $687,000 after acquiring an additional 59,600 shares in the last quarter. Finally, Warberg Asset Management LLC acquired a new stake in Intelligent Bio Solutions in the third quarter worth about $46,000. Hedge funds and other institutional investors own 32.97% of the company’s stock.

About Intelligent Bio Solutions

Intelligent Bio Solutions, Inc, through its wholly owned subsidiary, is focused on the design, development and marketing of rapid, real-time detection and identification systems for foodborne and environmental pathogens. The company’s flagship product, the RAPID-B System, integrates patented biosensor and fluorescence technologies to detect viable microorganisms in a fraction of the time required by traditional culture-based testing methods. This approach enables food processors, beverage producers, environmental testing laboratories and homeland security agencies to identify contaminants such as Escherichia coli O157:H7, Salmonella spp.